Zafgen, Inc. (ZFGN) Receives $9.00 Consensus PT from Brokerages

Zafgen, Inc. (NASDAQ:ZFGN) has been given an average recommendation of “Hold” by the five ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $9.00.

ZFGN has been the subject of several recent analyst reports. ValuEngine raised Zafgen from a “strong sell” rating to a “sell” rating in a report on Thursday, July 6th. Zacks Investment Research lowered Zafgen from a “buy” rating to a “hold” rating in a report on Friday, September 15th.

In other news, Director Frances K. Heller acquired 10,000 shares of Zafgen stock in a transaction on Friday, October 13th. The stock was acquired at an average cost of $3.90 per share, with a total value of $39,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 21.20% of the stock is currently owned by corporate insiders.

Several large investors have recently bought and sold shares of ZFGN. Wells Fargo & Company MN lifted its position in shares of Zafgen by 1,290.3% during the first quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 40,400 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Zafgen by 5.9% during the first quarter. Bank of New York Mellon Corp now owns 104,199 shares of the biopharmaceutical company’s stock worth $485,000 after acquiring an additional 5,794 shares in the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Zafgen by 55.8% during the first quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock worth $134,000 after acquiring an additional 10,327 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Zafgen by 937.6% in the first quarter. JPMorgan Chase & Co. now owns 495,743 shares of the biopharmaceutical company’s stock worth $2,311,000 after buying an additional 447,964 shares in the last quarter. Finally, TIAA CREF Investment Management LLC raised its position in shares of Zafgen by 40.9% in the first quarter. TIAA CREF Investment Management LLC now owns 169,836 shares of the biopharmaceutical company’s stock worth $791,000 after buying an additional 49,308 shares in the last quarter. Hedge funds and other institutional investors own 48.53% of the company’s stock.

Zafgen (NASDAQ:ZFGN) traded up 1.45% on Thursday, reaching $3.50. The company’s stock had a trading volume of 171,761 shares. The firm’s 50-day moving average price is $3.52 and its 200 day moving average price is $3.78. Zafgen has a 52-week low of $2.89 and a 52-week high of $5.46. The company’s market cap is $96.19 million.

Zafgen (NASDAQ:ZFGN) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.03. During the same period in the prior year, the business earned ($0.55) earnings per share. Equities analysts anticipate that Zafgen will post ($2.23) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Zafgen, Inc. (ZFGN) Receives $9.00 Consensus PT from Brokerages” was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.truebluetribune.com/2017/11/14/zafgen-inc-zfgn-receives-9-00-consensus-pt-from-brokerages.html.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply